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Shentong Yu2, Jian Zhang2* and Wenchao Liu1*Abstract
Background: Tamoxifen, an endocrine therapy drug used to treat breast cancer, is designed to interrupt estrogen
signaling by blocking the estrogen receptor (ER). However, many ER-positive patients are low reactive or resistant to
tamoxifen. Metformin is a widely used anti-diabetic drug with noteworthy anti-cancer effects. We investigated
whether metformin has the additive effects with tamoxifen in ER-positive breast cancer therapy.
Methods: The efficacy of metformin alone and in combination with tamoxifen against ER-positive breast
cancer was analyzed by cell survival, DNA replication activity, plate colony formation, soft-agar, flow cytometry,
immunohistochemistry, and nude mice model assays. The involved signaling pathways were detected by
western blot assay.
Results: When metformin was combined with tamoxifen, the concentration of tamoxifen required for growth
inhibition was substantially reduced. Moreover, metformin enhanced tamoxifen-mediated inhibition of proliferation, DNA
replication activity, colony formation, soft-agar colony formation, and induction of apoptosis in ER-positive breast cancer
cells. In addition, these tamoxifen-induced effects that were enhanced by metformin may be involved in the bax/bcl-2
apoptotic pathway and the AMPK/mTOR/p70S6 growth pathway. Finally, two-drug combination therapy significantly
inhibited tumor growth in vivo.
Conclusion: The present work shows that metformin and tamoxifen additively inhibited the growth and augmented
the apoptosis of ER-positive breast cancer cells. It provides leads for future research on this drug combination for the
treatment of ER-positive breast cancer.
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Tamoxifen, a non-steroidal anti-estrogen, is the most
widely used anti-estrogen for the treatment or preven-
tion of estrogen receptor (ER)-positive breast cancer
[1,2]. For women with ER-positive breast cancer, treat-
ment for 5 years with adjuvant tamoxifen substantially
reduces the rate of recurrence [3]. Recent trials have
shown that continuing tamoxifen for 10 years rather
than stopping at 5 years produces a further reduction in* Correspondence: biozhangj@hotmail.com; xjcancer@fmmu.edu.cn
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unless otherwise stated.recurrence and mortality [4]. However, many ER positive
patients are low reactive or resistant to tamoxifen [3]
and such long treatment with tamoxifen causes serious
side-effects such as increases in endometrial hyperplasia
and carcinomas [5], an excess of venothrombotic episodes,
and the development of de novo or acquired tamoxifen
resistance [6,7]. Thus, there is the need for a more
effective therapy with fewer side-effects for these pa-
tients. Modulation of tamoxifen sensitivity that results
in lessening of its side-effects is a desirable goal.
Metformin (1,1-dimethylbiguanide hydrochloride) is a
biguanide commonly used to treat type 2 diabetes melli-
tus. It is frequently referred to as an “insulin sensitizer”
because it lowers circulating insulin levels in settings of
insulin resistance and hyperinsulinemia [8,9]. Much re-
cent interest has focused on the antitumor effects of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ma et al. BMC Cancer 2014, 14:172 Page 2 of 11
http://www.biomedcentral.com/1471-2407/14/172metformin. A recent retrospective analysis examined the
effects of metformin on potentiation of chemotherapy in
breast cancer patients and found that women with dia-
betes and breast cancer receiving metformin and neoad-
juvant chemotherapy experienced a higher pathologic
complete response rate than diabetic patients just receiv-
ing neoadjuvant chemotherapy, but not metformin [10].
This study generated substantial enthusiasm that metfor-
min might enhance the efficacy of other anti-tumor agents,
particularly endocrine drugs. In addition, emerging evi-
dence suggests that metformin may activate AMPK and in-
hibit mTOR signaling to exert anti-tumor effects [11-13].
Of note, tamoxifen also represses mTOR signaling to re-
strain ER-positive breast cancer growth [14]. In a phase II
GINECO study, everolimus, an mTOR inhibitor, also en-
hanced the efficacy of tamoxifen in ER-positive metastatic
breast cancer patients [15]. It was postulated that the pleio-
tropic actions of metformin on AMPK/mTOR signaling
might play an additive role with tamoxifen and allow its
use in non-diabetic patients and women with ER-positive
tumors.
Based on these considerations, we posed the following
questions: first, whether metformin and tamoxifen have
synergic effects on the growth of ER-positive breast can-
cer cells; second, whether AMPK/mTOR or other signal-
ing pathways are involved in the two-agent synergic
effects; and last, whether this synergic effect occurs
in vivo. In this study, we tested the hypothesis that the
combination of metformin and tamoxifen suppresses the
growth of ER-positive breast cancer, and we provide
evidence of basic research for future clinical trials.
Methods
Reagents and antibodies
Metformin (1,1-dimethylbiguanide hydrochloride), tamoxi-
fen (4-hydroxytamoxifen), thiazolyl blue tetrazolium brom-
ide (MTT), Giemsa stain, dimethyl sulfoxide (DMSO) and
agarose were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Metformin was dissolved in sterile water to
make a 1 M stock solution, and tamoxifen was dissolved in
ethanol to make a 3.2 mM stock solution. The Cell-
LightTM BrdU DNA Cell Proliferation Kit was purchased
from Ribobio (Guangzhou, China). The antibodies against
p-AMPK (Thr172), AMPK, p-mTOR (Ser2448), mTOR,
p-p70S6 (Thr389), p70S6, bcl-2 and bax are rabbit
monoclonals and were purchased from Cell Signaling
Technologies (Beverly, MA, USA). The antibody against
β-actin is a mouse monoclonal and was purchased from
Boster (Wuhan, China).
Cell culture
The human breast cancer cell lines MCF-7 and ZR-75-1
were obtained from the American Type Culture Collection.
The cells were cultured in DMEM supplemented with 10%fetal bovine serum (FBS) and were maintained in a humidi-
fied environment containing 5% CO2 and air at 37°C. The
culture medium of MCF-7 cells contained 0.01 mg/ml
insulin.Cell survival assay
Cells were seeded in a 96-well plate (5 × 103 cells per
well) and incubated for 24 h. After treatment with differ-
ent drugs for 48 or 96 h, the cells were then incubated
with 0.5 mg/ml MTT (Sigma). Four hours later, the
medium was replaced with 150 μl dimethyl sulfoxide
(DMSO) (Sigma) and vortexed for 10 min. Absorbance
was then recorded at 490 nm using an Infinite® F500
micro-plate reader (TECAN). Relative values of optical
density were calculated.DNA replication activity assay
DNA replication activity was examined using BrdU (5-
bromo-2-deoxyuridine). Cells grown on coverslips (Fisher)
were treated with different drugs for 48 h. The cells were
then incubated with BrdU for 1 h and stained with an anti-
BrdU antibody (Ribobio) according to the manufacturer’s
instructions. The results were analyzed using a fluorescence
microscope (Olympus).Plate colony formation assay
Cells (1 × 103) treated with different drugs were seeded
into 60 mm dishes with 5 ml of DMEM. After 10 days,
the resulting colonies were rinsed with PBS, fixed with
methanol at −4°C for 5 min, and stained with Giemsa
(Sigma) for 20 min. Counting was performed only on
clearly visible colonies (diameter > 50 μm).Soft-agar assay
Cells (1 × 103) were added to 3 ml of DMEM with 0.3%
agar and layered onto 6 ml of 0.5% agar beds in 60 mm
dishes. Cells were treated with different drugs and cul-
tured for 2 weeks, after which colonies were photo-
graphed. Colonies larger than 50 μm in diameter were
counted as positive for growth.Flow cytometry analysis
Cells (5 × 105) were collected and washed twice with
PBS and then resuspended in 500 μl of staining solution
containing fluorescein isothiocyanate (FITC)-conjugated
annexin V antibody (5 μl) and propidium iodide (PI, 5 μl
of 250 μg/ml stock solution). After incubation for 15 min
at room temperature in the dark, cells were immediately
analyzed on a flow cytometer. Apoptotic cells were double
stained with annexin V and PI. The percentage of cells
undergoing apoptosis was determined.
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Western blot was performed as described previously
[16]. The blots were probed with the different primary
antibodies and species-matched secondary antibodies.
The bands were detected using enhanced chemilumines-
cence (Pierce) or the Odyssey Imaging System (LiCor
Biosciences).
Xenograft study in nude mice
Three days after injection of estrogen in the abdomen (E2,
0.9 mg/kg, every three days), 5 × 106 MCF-7 cells were
injected into the abdominal mammary fat pad of 4-week-
old female nude mice. When tumor volume reached ap-
proximately 200 mm3, we randomly allocated the mice to
groups in which they received PBS, metformin, tamoxifen,
or a combination of the two drugs. Tumor growth was
monitored by caliper measurements. Excised tumors were
weighed, and portions were frozen in liquid nitrogen or
fixed in 4% paraformaldehyde for further study.
Animal ethics statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use
of Laboratory Animals of the Forth Military Medical
University. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Forth Military
Medical University. All surgery was performed under so-
dium pentobarbital anesthesia, and every effort was made
to minimize suffering.
Immunohistochemistry
Immunohistochemical staining was performed as de-
scribed previously [16] using rabbit anti-Ki67, anti-p-
AMPK, anti-p-mTOR, and anti-p-p70S6 from Cell
Signaling (Beverly, MA, USA) as primary antibodies.
Statistical analysis
Data from all quantitative assays are expressed as the
mean ± standard deviation and were analyzed statistically
using a one-way analysis of variance (ANOVA) and the
independent-samples t test. Statistical calculations were
performed using SPSS 14.0. P values of less than 0.05
were considered statistically significant.
Results
Inhibition of the viability of ER-positive breast cancer cells
by tamoxifen plus metformin
To assess the effect of combining tamoxifen with met-
formin on the viability of ER-positive breast cancer
cells, MCF-7 and ZR-75-1 cells were first treated with
tamoxifen or metformin individually. Cell proliferation
was measured at 2 and 4 days after treatment. The in-
hibitory effects of both tamoxifen and metformin on thetwo cell lines were significantly dose dependent and
at the concentration of about 8 μM tamoxifen or 20
mM metformin the cell survival curves began to drop
(Figure 1A-D). To avoid the inhibitory effect of high
concentration metformin on breast cancer cells, we
just used a low concentration metformin (5 mM) and
we combined 5 mM metformin with a low concentra-
tion tamoxifen (5 μM) or a high concentration tamoxi-
fen (10 μM) to investigate the additive effect of two
drugs. The results showed that the low concentrations
of metformin and tamoxifen additively inhibited MCF-
7 cell proliferation compared with the single tamoxifen
treatment (Figure 1E). Similar results were found using
the ZR-75-1 cell line (Figure 1F).
Inhibition of the DNA replication activity of ER-positive
breast cancer cells by tamoxifen plus metformin
DNA replication activity is a critical index for cell growth.
BrdU, a synthetic thymidine analogue that binds to replicat-
ing DNA, was used to examine the rate of DNA replication.
After 3 h incubation with BrdU, the cells in the DNA repli-
cation phase were labeled with a red color. As shown in
Figure 2A and B, 5 mM metformin or 5 μM tamoxifen
alone had little effect on MCF-7 DNA synthesis, but
the combination of the two agents significantly inhib-
ited DNA synthesis compared with the single-agent
treatments. Moreover, the combination of 5 mM met-
formin with 10 μM tamoxifen had an even larger in-
hibitory effect on DNA replication. The ZR-75-1 cell
line showed similar effects with the different treatment
conditions (Figure 2C and D).
Inhibition of colony formation of ER-positive breast cancer
cells by tamoxifen plus metformin
The colony formation of tumor cells represents the
degree of malignancy and tumorigenicity. We examined
the effect of tamoxifen plus metformin on the ability of
cells to form colonies using plate and soft-agar colony
formation assays. In long-term (10 or 14 days) clono-
genicity assays, 5 μM and 10 μM tamoxifen had weak
inhibitory effects on the colony formation of MCF-7 and
ZR-75-1 cells. However, after the addition of 5 mM met-
formin to the tamoxifen, the number of colonies formed
by the cells was reduced significantly (Figure 3A-D).
Similar inhibitory effects of the two agents were found
using a soft-agar colony formation assay (Figure 3E-H).
Promotion of apoptosis of ER-positive breast cancer cells
by tamoxifen plus metformin
Because the combination of tamoxifen plus metformin
caused a significant reduction in the growth of ER-
positive breast cancer cells, the underlying mechanisms
were investigated. First, we measured the induction of
Figure 1 Metformin and tamoxifen inhibit the viability of MCF-7 and ZR-75-1 cells. (A-B) MCF-7 and ZR-75-1 cells were treated with tamoxifen at
different concentrations (0, 0.25, 0.5, 1, 2, 4, 8, 16, 32 and 64 μM). After 2 or 4 days, the cell viability was measured. (C-D) MCF-7 and ZR-75-1 cells were
treated with metformin at different concentrations (0, 0.625, 1.25, 2.5, 5, 10, 20, 40, 80 and 160 mM). After 2 or 4 days, the cell viability was measured.
(E-F) MCF-7 and ZR-75-1 cells were treated with 5 or 10 μM tamoxifen, 5 mM metformin, or a combination of the two agents for 4 days, and the cell
viability was measured. Histograms represent quantification of cell viability. All data are expressed as the mean ± standard deviation (SD) from three
independent experiments. *P < 0.05 for the 5 μM Tam group vs. the 5 μM Tam+ 5 mM Met group; #P < 0.05 for the 10 μM Tam group vs. the 10 μM
Tam+ 5 mM Met group. Tam and Met represent tamoxifen and metformin, respectively.
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the agents individually or in combination and examined
by annexin V/propidium iodide staining (Figure 4A-D).
At the concentrations tested, single treatments of 5 μM
or 10 μM tamoxifen or 5 mM metformin produced a
minor rate of apoptosis, but the combination induced
apoptosis in almost 50% of the cells. To further examine
the processes of cell death induced by this combination,
we then analyzed cell extracts for the expression of
biological markers of apoptosis. Western blot results
showed that the combination drug treatment resulted in
significant induction of the pro-apoptotic gene bax,
whereas the expression of the anti-apoptotic gene bcl-2
was decreased (Figure 4E-F).Activation of AMPK and inhibition of mTOR/p70S6
signaling by tamoxifen plus metformin
To investigate the mechanisms by which tamoxifen plus
metformin induced growth inhibition, we first evaluated
the effects of metformin alone and found that metformin
increased the levels of activated AMPK (p-AMPK, with
no change in AMPK levels) in a time-dependent manner
in MCF-7 and ZR-75-1 cells (Figure 5A and B). The
phosphorylation of the signaling molecules downstream
of mTOR and p70S6, was significantly decreased follow-
ing treatment, yet the total levels of mTOR and p70S6
were minimally affected (Figure 5A and B). We then ex-
amined the effects of the combination of metformin and
tamoxifen on these signals. As shown in Figure 5C and 5D,
Figure 2 Metformin and tamoxifen inhibit the DNA replication activity of MCF-7 and ZR-75-1 cells. (A and C) MCF-7 and ZR-75-1 cells
were treated with 5 or 10 μM Tam, 5 mM Met, or 5 or 10 μM Tam+ 5 mM Met. After 2 days, the DNA replication activity of the cells was measured
by BrdU assay. A red color indicates cells in the DNA replication phase, and a blue color indicates the cell nucleus (scale bar = 20.0 μm).
(B and D) BrdU-positive cells were counted in five random high-power fields (original magnification, 400x). Histograms represent quantification of
BrdU-positive cells. All data are expressed as the mean ± standard deviation (SD) for three independent experiments. *P< 0.05 for the 5 μM Tam group vs.
the 5 μM Tam+ 5 mM Met group; #P< 0.05 for the 10 μM Tam group vs. the 10 μM Tam+ 5 mM Met group.
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phosphor-AMPK and a reduction in phosphor-mTOR and
phosphor-p70S6, but total AMPK, mTOR and p70S6 levels
were unchanged.
Metformin plus tamoxifen inhibit the growth of
ER-positive breast cancer in vivo
To further evaluate the effects of metformin alone and
in combination with tamoxifen on tumor growth in vivo,
MCF-7 cells were injected into nude mice. When the tu-
mors reached approximately 200 mm3, the mice were
then treated with metformin (2 mg/ml) in the animals’
drinking water, tamoxifen (60 mg/kg) by oral gavage, or
the two agents simultaneously. As shown in Figure 6A
and 6C, the combination (Met + Tam) group achieved a
sustained and significant arrest of tumor growth equal
to a 75.4% decrease in mean tumor volume on 24 day
after being treatment compared with the control group.
However, the groups that received metformin or tamoxi-
fen alone exhibited tumor growth that was inhibited by
48.9% and 43.8%, respectively, on 24 day after being
treatment compared with the control group. Moreover,
the mice were sacrificed, and the tumor weights wereexamined. The tumor weight of the combination treatment
group was the lightest of the four groups (Figure 6B).
Finally, immunolabeling for Ki-67, p-AMPK, p-mTOR and
p-p70S6 was analyzed. Consistent with results observed in
cultured cells, these proteins were lower in the two
groups receiving either metformin or tamoxifen com-
pared with the control group. Importantly, combining
the two agents significantly inhibited the expression of
these proteins (Figure 6D).
Discussion
Recently, the ATLAS clinical trial announced the latest
results that continuing tamoxifen to 10 years rather than
stopping at 5 years further reduces recurrence and mor-
tality in patients with ER-positive breast cancer [4]. This
is encouraging news for the efficacy of tamoxifen, al-
though its significant problems, therapeutic side-effects
and resistance, must still be addressed. Some epidemio-
logical studies suggest that metformin may exert anti-
tumor effects in diabetic patients with breast cancer
[10,17]. Because of its minor side-effects and low tox-
icity, metformin may be a desirable drug for the preven-
tion of breast cancers and the growth reduction of
Figure 3 (See legend on next page.)
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Figure 3 Metformin and tamoxifen inhibit the colony-forming ability of MCF-7 and ZR-75-1 cells. The colony formation assays were
performed as described in the “Methods”. (A, C, E and G) MCF-7 and ZR-75-1 cells were treated with 5 or 10 μM Tam, 5 mM Met, or 5, or 10 μM
Tam+ 5 mM Met. Typical cell colonies were imaged and are shown. (B, D, F and H) The number of colonies formed was counted for different
groups. Histograms represent the quantification of the number of colonies formed. All data are expressed as the mean ± standard deviation (SD)
for three independent experiments. *P< 0.05 for the 5 μM Tam group vs. the 5 μM Tam+ 5 mM Met group; #P< 0.05 for the 10 μM Tam group vs. the
10 μM Tam+ 5 mM Met group.
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of metformin on endocrine therapies for ER-positive
breast cancer patients are largely unknown. Based on
this consideration, we investigated the efficacy of low-
concentration doses of metformin alone or in combination
with tamoxifen in a model of ER-positive breast cancer that
reflects treatment strategies in common clinical use. In this
study, we demonstrate that metformin enhanced the inhibi-
tory effects of tamoxifen on the growth of ER-positive
breast cancer in vitro and in vivo. Notably, when metformin
was combined with tamoxifen, the concentration of tam-
oxifen required to inhibit growth was substantially reduced.
Our observations indicate the potential importance of suchFigure 4 Metformin and tamoxifen promote the apoptosis of MCF-7 a
10 μM Tam, 5 mM Met, or 5 or 10 μM Tam + 5 mM Met. After 4 days, apop
used to examine apoptosis of the cells. (B and D) Histograms represent th
the 5 μM Tam + 5 mM Met group; #P < 0.05 for the 10 μM Tam group vs. t
were treated with 5 mM Met, 10 μM Tam or 10 μM Tam+ 5 mM Met for 4
expression of the target proteins was normalized to β-actin.combined approaches for increasing tamoxifen efficacy or
lessening its side-effects in the clinical setting.
Metformin is widely used for the treatment of diabetes
mellitus type 2, where it reduces insulin resistance and
diabetes-related morbidity and mortality [8,9]. Population-
based studies show that metformin treatment is associated
with a dose-dependent reduction in cancer risk [21,22].
Metformin treatment also increases complete pathological
tumor response rates following neoadjuvant chemotherapy
for breast cancer, suggesting a potential role as an anti-
cancer drug [23-25]. Diabetes mellitus type 2 is associated
with insulin resistance, elevated insulin levels and an in-
creased risk of cancer and cancer-related mortality [26,27].nd ZR-75-1 cells. MCF-7 and ZR-75-1 cells were treated with 5 or
tosis was measured. (A and C) Annexin/propidium iodide staining was
e quantification of apoptotic cells. *P < 0.05 for the 5 μM Tam group vs.
he 10 μM Tam + 5 mM Met group. (E and F) MCF-7 and ZR-75-1 cells
days. Protein was extracted and subjected to western blot. The
Figure 5 Detection of the AMPK/mTOR signaling pathway after combination treatment with metformin and tamoxifen in MCF-7 and
ZR-75-1 cells. (A-B) MCF-7 and ZR-75-1 cells were treated with 5 mM Met for different times (0, 6, 12, 18, 24 and 48 hours). (C-D) MCF-7 and
ZR-75-1 cells were treated with 5 mM Met, 10 μM Tam or 10 μM Tam+ 5 mM Met for 2 days. Protein was extracted and subjected to western
blot. The expression of the target proteins was normalized to β-actin.
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the insulin and insulin-like growth factor (IGF) signaling
pathways and increased signaling through the estrogen re-
ceptor [28,29]. Reversal of these processes through reduc-
tion of insulin resistance by the oral anti-diabetic drug
metformin is an attractive anti-cancer strategy. In this
study, we also provide direct evidence that metformin
acts additively with endocrine therapy for ER-positive
breast cancer patients, who account for almost 70% of
all breast cancers. Metformin enhanced the inhibitory
effects of tamoxifen on proliferation, DNA replication
activity, colony formation, and soft-agar colony forma-
tion in ER-positive breast cancer cells. An increasing
number of studies suggest that metformin is an activa-
tor of AMPK, which inhibits protein synthesis and
gluconeogenesis during cellular stress [12-14]. The
main downstream effect of AMPK activation is the
inhibition of mTOR signaling pathways [13,14]. Here
we showed that in a time-dependent manner, met-
formin increased p-AMPK and decreased p-mTORexpression. p70S6, one of the critical downstream
effectors of the mTOR signaling pathway, was also
inhibited.
We found that the specific clinical circumstances in
which metformin may be used in ER-positive breast can-
cer patients substantially influenced responsiveness to
this agent. Our data are the first to examine the individ-
ual and combined effects of metformin and tamoxifen
on a nude mouse model of ER-positive breast cancer
and to investigate the apoptotic and growth pathways in-
volved. Prior to this study, to our knowledge, there were
two articles that described the effects of the combination
of metformin and tamoxifen. One investigation sug-
gested that metformin may decrease the density of endo-
metrial glands and hyperplasia induced by tamoxifen in
a mouse model [30]. The other team found that metfor-
min and tamoxifen inhibited the proliferation of MCF-7
cells and that tamoxifen-resistant cells were less sensitive
to tamoxifen than to metformin [31]. That study pro-
vided the important clue that metformin may exert an
Figure 6 Inhibitory effects of metformin and tamoxifen on tumor growth in a nude mouse model. These experiments were
performed as described in the “Methods”. When the tumors in nude mice reached 200 mm3, the mice were given metformin (2 mg/ml) in
their drinking water, tamoxifen (60 mg/kg) through oral gavage or the two agents simultaneously. The tumor growth was assessed every
3 days until day 24 of treatment by measuring two perpendicular diameters and calculating the volume in mm3. (A) Photographs of typical
tumors are shown. (B) Histograms represent the weight of tumors from the different groups. (C) Tumor growth curve. Statistical analysis
was performed using one-way ANOVA and Student’s t-test day with the day 24 values only. *P < 0.05 compared with the Tam group.
(D) Intratumoral target protein expression was assessed by Ki67, p-AMPK, p-mTOR and p-p70S6 immunolabeling on paraffin-embedded
tumor sections. Representative images are shown (original magnification, 400x).
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consistent with our results that metformin and tamoxi-
fen inhibit the growth of MCF-7 cells. The focus of our
study was a wild-type, ER-positive breast cancer model,
which represents patients receiving initial tamoxifen treat-
ment. For these patients, it is possible that metformin
additively augments tamoxifen efficacy but also suppresses
tumor cell growth.Conclusion
Taken together, our data indicate that metformin plus
tamoxifen may have synergic effects on ER-positive
breast cancer cells and tumor growth. We have fur-
ther confirmed that these synergic effects of the two
agents may be involved in the bax/bcl-2 apoptotic
pathway and the AMPK/mTOR/p70S6 growth path-
way. Although the antitumor effect of metformin is
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ings provide direct evidence of its efficacy on ER-
positive breast cancer in combination with tamoxifen
treatment.
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